Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Astrazeneca plc | History Defined

AstraZeneca's Hard To Control Hypertension Drug Advances, With FDA Decision Expected In 2026

On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ:AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or treatment-resistant) hypertension as an add-on to other antihypertensive medicines.

Benzinga

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Benzinga

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN), initially established in March 2025.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.

Benzinga

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans

President Donald Trump is reportedly set to announce a new agreement with AstraZeneca Plc (NASDAQ:AZN) designed to reduce prescription drug costs for Americans.

Benzinga

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Bax24 Phase 3 trial to evaluate the safety, tolerability, and the effect of 2mg baxdrostat versus placebo.

Benzinga

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NASDAQ:AZN) to accelerate the discovery of novel therapeutic targets in immunology.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Benzinga

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.

Benzinga

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.

Benzinga

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

StockNews.com

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

Barchart

Stocks See Support from Positive Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. March E-mini S&P futures (ESH25 ) are up by +0.07%, and March E-mini Nasdaq...

Barchart

Stocks Find Support From Strong Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.29%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.18%. March E-mini S&P futures (ESH25 ) are up by +0.21%, and March E-mini Nasdaq...

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Global Stocks to Diversify Your Portfolio

Markets outside the United States don’t always move in sync with domestic trends, which means adding international stocks can help reduce volatility and spread risk. Thus, investors looking to diversify their portfolio can consider investing in fundamentally sound companies like SAP SE (SAP), AstraZeneca (AZN), and Alibaba Group (BABA) for…

StockNews.com

3 Blue-Chip Stocks for Long-Term Stability

With uncertainty looming over the stock market, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, Walmart (WMT), The Procter & Gamble (PG), and AstraZeneca (AZN), for stable results. Read more….

StockNews.com

3 A-Rated Pharma Stocks to Buy for Long-Term Growth

With surging medical needs, advances in precision medicine, and the adoption of generative AI, the pharmaceutical industry is thriving. Thus, it could be ideal to invest in quality pharma stocks Taro Pharmaceutical (TARO), AstraZeneca (AZN), and Merck (MRK) for long-term growth. These stocks are rated A (Strong Buy) in our…

StockNews.com

3 Pharma Powerhouses for Long-Term Growth in 2024

Amid evolving technologies and strategic maneuvers, the pharma industry is set for paradigm-shifting growth, propelled by growing funding and drug discovery. Hence, fundamentally strong pharma stocks Collegium Pharmaceutical (COLL), AstraZeneca (AZN), and Merck & Co. (MRK) might be ideal buys this year for long-term growth. Read more….

StockNews.com

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

StockNews.com

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

3 Top-Rated Pharma Stock Picks to Consider in the New Year

The pharmaceutical industry is expected to grow rapidly due to rising global medical needs and technological advancements. With the industry expected to thrive in the coming years, it could be wise to buy Zoetis (ZTS), AstraZeneca (AZN) and Taro Pharmaceutical (TARO) for steady returns. Read more.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Dow Jones Industrials

316 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.